May 2024 Publications

By WGNV | June 12, 2024

Demonstrating the utility of the ex vivo murine mycobacterial growth inhibition assay (MGIA) for high-throughput screening of tuberculosis vaccine candidates against multiple Mycobacterium tuberculosis complex strains. Painter H, Willcocks S, Zelmer A, Reljic R, Tanner R, Fletcher H. Tuberculosis (Edinb). 2024 May. doi: 10.1016/j.tube.2024.102494. Epub 2024 Feb 13.   Recognition of Mycobacterium tuberculosis by macrophage…

Read More

April 2024 Publications

By WGNV | May 14, 2024

Perspectives on development and advancement of new tuberculosis vaccines. da Costa C, Benn CS, Nyirenda T, Mpabalwani E, Grewal HMS, Ahmed R, Kapata N, Nyasulu PS, Maeurer M, Hui DS, Goletti D, Zumla A. Int J Infect Dis. 2024 Apr. doi: 10.1016/j.ijid.2024.106987. Epub 2024 Feb 26.  Comparative transcriptomics reveals common and strain-specific responses of human…

Read More

Summary: 2023 Working Group on New TB Vaccines Annual Meeting

By WGNV | February 15, 2024

The Stop TB Partnership Working Group on New TB Vaccines (WGNV) held its first annual meeting on 14 November 2023. The meeting was part of a full-day New TB Tools Summit – a collaboration between WGNV, the Stop TB Partnership’s Working Group on New Drugs and New Diagnostics Working Group, TB Alliance, FIND, and IAVI…

Read More